Sustained release preparation of roxithromycin
A technology of roxithromycin and sustained-release preparations, applied in the field of medicine, can solve the problems of short effective blood drug concentration time, many times of taking, gastrointestinal side effects, etc., to reduce gastrointestinal side effects, improve curative effect, and improve taste sense of effect
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0016] The present embodiment 1 tablet that adopts the known method of pharmaceutical industry to make contains following composition by weight percentage:
[0017] Roxithromycin 50%
[0018] Citric Acid 10%
[0019] HPMCK15M (Methocel K15MCR) 15%
[0020] Lactose 10%
[0021] Microcrystalline Cellulose 6%
[0022] 3% hydroxypropyl methylcellulose ethanol solution (3% HPMC ethanol solution) 3%
[0023] Stearic acid 2%
[0024] Talc 3%
[0026] HPMCK15M is a hydrophilic polymer, which is a skeleton material in this preparation, which swells with water or digestive juice to form a gel barrier to control the diffusion of roxithromycin and achieve the purpose of sustained release.
[0027] Among them, HPMCK15M can be replaced by different dosages of HPMCK100LV, HPMCK4M or HPMCK100M, or used in combination to adjust the drug release curve.
Embodiment 2
[0029] The present embodiment 2 tablet that adopts the known method of pharmaceutical industry to make contains following composition by weight percentage:
[0030] Roxithromycin 70%
[0031] Citric Acid 10%
[0032] Carbopol 18%
[0033] Stearic acid 1%
[0034] Talc 1.5%
[0035] Magnesium Stearate 0.5%
[0036] Hydrophilic polymer carboxyvinyl (carbomer) is the skeleton material, which expands to form a gel barrier when it encounters water or digestive juice, and controls the diffusion of roxithromycin to achieve the purpose of sustained release.
Embodiment 3
[0038] The present embodiment 3 tablet that adopts the known method of pharmaceutical industry to make contains following composition by weight percentage:
[0039] Roxithromycin 50%
[0040] Citric Acid 10%
[0041] Sodium Alginate 18%
[0042] Calcium Alginate 3%
[0043] Lactose 11%
[0044] Polyvinylpyrrolidone 6%
[0045] Stearic acid 1%
[0046] Talc 13%
[0047] Magnesium Stearate 0.5%
[0048] The insoluble salt and soluble salt of the hydrophilic polymer alginic acid are used as the skeleton material, which swells with water or digestive juice to form a cross-linked gel barrier to control the diffusion of roxithromycin and achieve the purpose of sustained release.
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com